万邦医药(301520.SZ)发布2023年度业绩，净利润1.08亿元，增长9.48%

智通财经网04-19

万邦医药(301520.SZ)发布2023年年度报告，该公司营业收入为3.42亿元，同比增长31.07%。归属于上市公司股东的净利润为1.08亿元，同比增长9.48%。归属于上市公司股东的扣除非经常性损益的净利润为9769.52万元，同比增长12.89%。基本每股收益为2元。此外，拟向全体股东每10股派发现金红利5元(含税)。公告显示，公司是一家同时提供药学研究和临床研究服务的综合型CRO企业，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428658546?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-19 19:28","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2428658546","market":"other","top_or_hot":-1,"title":"万邦医药(301520.SZ)发布2023年度业绩，净利润1.08亿元，增长9.48%","media":"智通财经网","content":"<div>\n<p>万邦医药(301520.SZ)发布2023年年度报告，该公司营业收入为3.42亿元，同比增长31.07%。归属于上市公司股东的净利润为1.08亿元，同比增长9.48%。归属于上市公司股东的扣除非经常性损益的净利润为9769.52万元，同比增长12.89%。基本每股收益为2元。此外，拟向全体股东每10股派发现金红利5元(含税)。公告显示，公司是一家同时提供药学研究和临床研究服务的综合型CRO企业，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>万邦医药(301520.SZ)发布2023年度业绩，净利润1.08亿元，增长9.48%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n万邦医药(301520.SZ)发布2023年度业绩，净利润1.08亿元，增长9.48%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 19:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>万邦医药(301520.SZ)发布2023年年度报告，该公司营业收入为3.42亿元，同比增长31.07%。归属于上市公司股东的净利润为1.08亿元，同比增长9.48%。归属于上市公司股东的扣除非经常性损益的净利润为9769.52万元，同比增长12.89%。基本每股收益为2元。此外，拟向全体股东每10股派发现金红利5元(含税)。公告显示，公司是一家同时提供药学研究和临床研究服务的综合型CRO企业，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301520","symbol_name":"万邦医药","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml","article_id":"2428658546","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2428658546","pubTimestamp":1713526080,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"万邦医药发布2023年年度报告，该公司营业收入为3.42亿元，同比增长31.07%。归属于上市公司股东的净利润为1.08亿元，同比增长9.48%。基本每股收益为2元。此外，拟向全体股东每10股派发现金红利5元(含税)。公告显示，公司是一家同时提供药学研究和临床研究服务的综合型CRO企业，通过合同形式为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司成立于2006年，是国内较早提供药物研发服务的CRO企业之一。股市回暖，抄底炒股先开户！","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"301520":"万邦医药"},"translate_title":"Wanbang Pharmaceutical (301520. SZ) released its 2023 annual results, with a net profit of 108 million yuan, an increase of 9.48%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301520":1},"content_text":"万邦医药(301520.SZ)发布2023年年度报告，该公司营业收入为3.42亿元，同比增长31.07%。归属于上市公司股东的净利润为1.08亿元，同比增长9.48%。归属于上市公司股东的扣除非经常性损益的净利润为9769.52万元，同比增长12.89%。基本每股收益为2元。此外，拟向全体股东每10股派发现金红利5元(含税)。公告显示，公司是一家同时提供药学研究和临床研究服务的综合型CRO企业，通过合同形式为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司成立于2006年，是国内较早提供药物研发服务的CRO企业之一。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428658546"}